Evidence map›Paper›PMID 23633956›Full record

ArticlePLoS pathogens2013

Immunodomination during peripheral vaccinia virus infection.

Leon C W Lin, Inge E A Flesch, David C Tscharke

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Direct Priming of CD8Journal of virology · 2021
    Article
  7. Article
  8. Surprisingly Effective Priming of CD8Journal of virology · 2020
    Article
  9. Vaccines · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Most viral peptides displayed by class I MHC on infected cells are immunogenic.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8Journal of immunology (Baltimore, Md. : 1950) · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leon C W LinDivision of Biomedical Science and Biochemistry, Research School of Biology, The Australian National University, Canberra, Australian Capital Territory, Australia.
Inge E A Flesch
David C Tscharke
Australian National University · AU

Funding

CD8+ T cell specificity in mouse models of smallpox vaccination and challengeR01AI067401 · NIAID · AUSTRALIAN NATIONAL UNIVERSITY · PI TSCHARKE, DAVID CARL · 2006 to 2008
$736k
NIAID NIH HHS R01 AI067401NIAID NIH HHS R01AI067401
6 · The paper itself

Abstract

Immunodominance is a fundamental property of CD8(+) T cell responses to viruses and vaccines. It had been observed that route of administration alters immunodominance after vaccinia virus (VACV) infection, but only a few epitopes were examined and no mechanism was provided. We re-visited this issue, examining a panel of 15 VACV epitopes and four routes, namely intradermal (i.d.), subcutaneous (s.c.), intraperitoneal (i.p.) and intravenous (i.v.) injection. We found that immunodominance is sharpened following peripheral routes of infection (i.d. and s.c.) compared with those that allow systemic virus dissemination (i.p. and i.v.). This increased immunodominance was demonstrated with native epitopes of VACV and with herpes simplex virus glycoprotein B when expressed from VACV. Responses to some subdominant epitopes were altered by as much as fourfold. Tracking of virus, examination of priming sites, and experiments restricting virus spread showed that priming of CD8(+) T cells in the spleen was necessary, but not sufficient to broaden responses. Further, we directly demonstrated that immunodomination occurs more readily when priming is mainly in lymph nodes. Finally, we were able to reduce immunodominance after i.d., but not i.p. infection, using a VACV expressing the costimulators CD80 (B7-1) and CD86 (B7-2), which is notable because VACV-based vaccines incorporating these molecules are in clinical trials. Taken together, our data indicate that resources for CD8(+) T cell priming are limiting in local draining lymph nodes, leading to greater immunodomination. Further, we provide evidence that costimulation can be a limiting factor that contributes to immunodomination. These results shed light on a possible mechanism of immunodomination and highlight the need to consider multiple epitopes across the spectrum of immunogenicities in studies aimed at understanding CD8(+) T cell immunity to viruses.

Indexed as

AnimalsAntigens, ViralB7-1 AntigenB7-2 AntigenCD8-Positive T-LymphocytesCricetinaeEpitopes, T-LymphocyteImmunodominant EpitopesLymph NodesMiceMice, Inbred C57BLMice, TransgenicSmallpox VaccineVacciniaVaccinia virusViral Envelope ProteinsAntigens, ViralB7-1 AntigenB7-2 AntigenEpitopes, T-Lymphocyteglycoprotein B, herpes simplex virus type 2Immunodominant EpitopesSmallpox VaccineViral Envelope Proteins

Identifiers

PMID23633956
PMCPMC3635974
OpenAlexW2149475402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.